Results 51 to 60 of about 3,454 (177)

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source

Intravitreal dexamethasone implant in the crystalline lens

JCRS Online Case Reports, 2014
We report the case of a 58-year-old man who developed macular edema due to superior temporal vein occlusion in his right eye. A dexamethasone implant was inadvertently injected into the crystalline lens. Slitlamp examination revealed the position of the implant. The intralenticular dexamethasone implant was clearly imaged in front of the posterior lens
Aylin Karalezli, Fatma Corak Eroglu
openaire   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trial

Trials
Background Proliferative diabetic retinopathy (PDR) often leads to tractional retinal detachment and vitreous hemorrhage, requiring vitrectomy. Poor visual outcomes are commonly caused by macular edema and proliferative vitreous retinopathy after ...
Jipeng Li, Zhaoyang Wang, Aman Chandra, Jun Xu, Lin Liu, Meng Zhao   +5 more
doaj   +1 more source

Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration

BMC Ophthalmology, 2019
Background This study aimed to investigate the incidence of and risk factors for the anterior chamber migration of an intravitreal dexamethasone implant (Ozurdex®).
D. Röck, K. U. Bartz-Schmidt, T. Röck
doaj   +1 more source

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review

BMC Ophthalmology, 2018
Background Cystoid macular oedema (CMO) is an uncommon complication associated with hydroxychloroquine (HCQ) retinopathy threatening central vision. We report a patient with HCQ retinopathy and CMO, for which an intravitreal dexamethasone implant was ...
Seong Joon Ahn, Jooyoung Joung, Sang Hyup Lee, Byung Ro Lee   +3 more
doaj   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, Volume 15, Issue 23, 19 June 2026.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Intravitreal Dexamethasone Implant (Ozurdex) for Ocular Toxocariasis

Journal of Ophthalmology
This study aimed to evaluate the efficacy and safety of intravitreal dexamethasone implants in the treatment of ocular toxocariasis (OT). A retrospective analysis was performed on 6 cases in which laboratory tests diagnosed OT. All patients were administered with intravitreal dexamethasone implants with or without vitrectomy. The average follow‐up time
Yongwei Zhou, Fangyuan Zhen, Jiahui Wu, Shasha Wang, Xiaoyan Lu, Ge Yang, Zhirou Hu, Fei Chen, Qiuming Li, Shuqian Dong   +9 more
openaire   +3 more sources

Staphylococcus lugdunensis endophthalmitis following dexamethasone intravitreal implant

Indian Journal of Ophthalmology, 2019
We present a unique case of endophthalmitis with Staphylococcus lugdunensis following dexamethasone intravitreal implant for branch retinal vein occlusion associated with cystoid macular edema. Patient did not show favorable clinical response after vitrectomy and intravitreal antibiotics; so, we decided to repeat vitrectomy, remove the steroid implant ...
Silvia Olivia Salceanu, Dina Hamada, Ramona Gabriela Ursu, Ahmed Abdelwahab Saad   +3 more
openaire   +3 more sources

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Clinical Ophthalmology, 2010
Jane S Myung, Grant D Aaker, Szilárd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan,
Jane S Myung, Grant D Aaker, Szilárd Kiss   +2 more
doaj